Globus Medical Q2 2024 Adj. EPS $0.75 Beats $0.68 Estimate, Sales $629.700M Beat $615.345M Estimate
Portfolio Pulse from Benzinga Newsdesk
Globus Medical (NYSE:GMED) reported Q2 2024 adjusted EPS of $0.75, beating the estimate of $0.68. Sales were $629.7M, surpassing the $615.345M estimate and showing a 115.94% increase from the same period last year.
August 06, 2024 | 8:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Globus Medical reported strong Q2 2024 earnings with an adjusted EPS of $0.75, beating estimates by 10.29%. Sales of $629.7M also surpassed expectations and increased by 115.94% YoY.
The strong earnings and revenue beat, along with significant year-over-year growth, are likely to positively impact GMED's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100